
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is a promising medical device and biopharmaceutical company led by new CEO Robert Goodman, who is focused on accelerating the adoption of the company's LungFit PH product, expanding international operations, and achieving revenue generation. Early data for their Beyond Cancer treatment shows promising results, and while the termination of a previous agreement presents some financial risks, the company remains committed to maximizing value for their NeuroNOS asset through alternative partnerships. The company also faces potential risks in the areas of clinical development, third-party dependency, intellectual property, and operational and employee issues.
Bears say
Beyond Air is currently undergoing a leadership change and bringing in a new Chief Commercial Officer, indicating a focus on driving sales and expanding market adoption for its nitric oxide platform. With a strong background in commercial operations, the new CCO, Mr. Goodman, is expected to accelerate the company's business strategy and push for increased utilization in the US and improved execution internationally. This focus on the commercial aspects of the business is critical as Beyond Air continues to prioritize its current primary driver, the LungFit PH system, and pursue additional pulmonary indications, while also maintaining the longer-term potential of its NeuroNOS platform.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares